JP2022522787A5 - - Google Patents
Info
- Publication number
- JP2022522787A5 JP2022522787A5 JP2021551806A JP2021551806A JP2022522787A5 JP 2022522787 A5 JP2022522787 A5 JP 2022522787A5 JP 2021551806 A JP2021551806 A JP 2021551806A JP 2021551806 A JP2021551806 A JP 2021551806A JP 2022522787 A5 JP2022522787 A5 JP 2022522787A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- fusion protein
- linker
- terminus
- sequence shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910162060 | 2019-03-05 | ||
| CN201910162060.6 | 2019-03-05 | ||
| CN201910758104.1 | 2019-08-16 | ||
| CN201910758104 | 2019-08-16 | ||
| PCT/CN2020/077750 WO2020177712A1 (en) | 2019-03-05 | 2020-03-04 | A polypeptide molecule and application thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022522787A JP2022522787A (ja) | 2022-04-20 |
| JP2022522787A5 true JP2022522787A5 (cg-RX-API-DMAC7.html) | 2023-02-09 |
| JP7664168B2 JP7664168B2 (ja) | 2025-04-17 |
Family
ID=72338401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021551806A Active JP7664168B2 (ja) | 2019-03-05 | 2020-03-04 | ポリペプチド分子及びその適用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12590132B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3935075A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7664168B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210137093A (cg-RX-API-DMAC7.html) |
| CN (2) | CN118388627A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2020230668B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3123325A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020177712A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112661858A (zh) * | 2020-12-03 | 2021-04-16 | 安徽安科生物工程(集团)股份有限公司 | 重组人生长激素Fc融合蛋白和用途及其工程细胞株 |
| US20240165202A1 (en) * | 2021-03-19 | 2024-05-23 | Sunshine Lake Pharma Co., Ltd. | Uses of fgf21 polypeptides and fusion polypeptides thereof |
| WO2023284822A1 (en) * | 2021-07-14 | 2023-01-19 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion polypeptides for metabolic disorders |
| CN115991793A (zh) * | 2023-01-16 | 2023-04-21 | 上海民为生物技术有限公司 | 具有多重活性的融合蛋白及其应用 |
| KR20250140132A (ko) * | 2023-01-18 | 2025-09-24 | 상하이 민웨이 바이오테크놀로지 씨오 엘티디 | 삼중 활성을 갖는 융합 단백질 및 그 용도 |
| JP2026520995A (ja) * | 2023-06-20 | 2026-06-25 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | GLP-1-Fc-FGF21二重標的融合タンパク質組成物、注射液、及びその使用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110893A (en) * | 1995-06-05 | 2000-08-29 | Human Genome Sciences, Inc. | Fibroblast growth factor 11 |
| ES2371072T3 (es) * | 2003-06-12 | 2011-12-27 | Eli Lilly And Company | Proteínas de fusión análogas de glp-1. |
| PL1751184T3 (pl) | 2004-05-13 | 2010-02-26 | Lilly Co Eli | Białka fuzyjne FGF-21 |
| BRPI0514790A (pt) | 2004-09-02 | 2008-06-24 | Lilly Co Eli | muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano |
| EP1789443A1 (en) | 2004-09-02 | 2007-05-30 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| JP2008522617A (ja) | 2004-12-14 | 2008-07-03 | イーライ リリー アンド カンパニー | 線維芽細胞成長因子21の突然変異タンパク質 |
| US20110034373A1 (en) | 2007-08-03 | 2011-02-10 | Eli Lilly And Company | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
| SG193860A1 (en) | 2008-06-04 | 2013-10-30 | Amgen Inc | Fgf21 mutants and uses thereof |
| NZ592009A (en) | 2008-10-10 | 2012-11-30 | Amgen Inc | Fgf21 mutants and uses thereof |
| DK3178835T3 (da) * | 2009-02-03 | 2019-06-24 | Amunix Pharmaceuticals Inc | Forlængede rekombinante polypeptider og sammensætninger omfattende samme |
| BRPI1011404B1 (pt) | 2009-05-05 | 2022-05-03 | Amgen Inc | Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira |
| AU2010246038A1 (en) | 2009-05-05 | 2011-12-01 | Amgen Inc. | FGF21 mutants and uses thereof |
| CN101993496B (zh) | 2009-08-20 | 2013-06-05 | 重庆富进生物医药有限公司 | 双重调节血糖血脂融合蛋白及其制法和用途 |
| WO2013033452A2 (en) | 2011-08-31 | 2013-03-07 | Amgen Inc. | Method of treating or ameliorating type 1 diabetes using fgf21 |
| US9458214B2 (en) * | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
| AR087973A1 (es) * | 2011-10-04 | 2014-04-30 | Lilly Co Eli | Variantes del factor 21 del crecimiento de fibroblastos |
| JP2015522539A (ja) | 2012-05-15 | 2015-08-06 | イーライ リリー アンド カンパニー | 線維芽細胞増殖因子21タンパク質の治療目的の使用 |
| TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子21蛋白質 |
| AU2013274639A1 (en) | 2012-06-11 | 2014-11-06 | Eli Lilly And Company | Fibroblast growth factor 21 variants |
| AR092076A1 (es) | 2012-08-22 | 2015-03-18 | Lilly Co Eli | Proteinas homodimericas |
| WO2015038938A1 (en) * | 2013-09-13 | 2015-03-19 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
| WO2015061351A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use |
| WO2016048999A2 (en) * | 2014-09-23 | 2016-03-31 | Salk Institute For Biological Studies | Fgf21 truncations and mutants and uses thereof |
| KR20160088656A (ko) * | 2015-01-16 | 2016-07-26 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| CN106397569B (zh) * | 2015-08-01 | 2020-09-01 | 深圳红石科创生物科技发展有限公司 | 一种治疗代谢疾病的突变细胞因子融合蛋白 |
| CA3000697A1 (en) | 2015-10-01 | 2017-04-06 | Amgen Inc. | Treatment of bile acid disorders |
| KR102670157B1 (ko) | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
| KR102668200B1 (ko) | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| WO2017116207A1 (ko) * | 2015-12-31 | 2017-07-06 | 한미약품 주식회사 | Fgf21 아날로그, fgf21 결합체, 및 이의 용도 |
| US20190142963A1 (en) | 2016-04-15 | 2019-05-16 | Richard D. DiMarchi | Fgf21 c-terminal peptide optimization |
| CN107759697B (zh) * | 2016-08-19 | 2023-03-24 | 安源医药科技(上海)有限公司 | 制备融合蛋白的方法 |
| HUE071618T2 (hu) | 2016-11-10 | 2025-09-28 | Yuhan Corp | Fúziós fehérjéket tartalmazó gyógyszerkészítmény hepatitisz, májfibrózis és májzsugor megelõzésére vagy kezelésére |
| CN108440668A (zh) | 2017-02-16 | 2018-08-24 | 瑞阳(苏州)生物科技有限公司 | Fgf21与igf-1的融合蛋白及其应用 |
| WO2018166461A1 (en) * | 2017-03-14 | 2018-09-20 | Sunshine Lake Pharma Co., Ltd. | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
| CN108623691B (zh) * | 2017-03-17 | 2020-05-15 | 北京比洋生物技术有限公司 | IgG样长效免疫融合蛋白及其应用 |
| CN116098989B (zh) * | 2018-02-08 | 2026-03-20 | 广东东阳光药业股份有限公司 | Fgf21变体、融合蛋白及其应用 |
-
2020
- 2020-03-04 AU AU2020230668A patent/AU2020230668B2/en active Active
- 2020-03-04 US US17/418,624 patent/US12590132B2/en active Active
- 2020-03-04 CN CN202410496064.9A patent/CN118388627A/zh active Pending
- 2020-03-04 CA CA3123325A patent/CA3123325A1/en active Pending
- 2020-03-04 JP JP2021551806A patent/JP7664168B2/ja active Active
- 2020-03-04 WO PCT/CN2020/077750 patent/WO2020177712A1/en not_active Ceased
- 2020-03-04 EP EP20767280.9A patent/EP3935075A4/en active Pending
- 2020-03-04 KR KR1020217031717A patent/KR20210137093A/ko not_active Ceased
- 2020-03-04 CN CN202010143690.1A patent/CN111662373B/zh active Active
-
2025
- 2025-08-21 US US19/306,596 patent/US20260139020A1/en active Pending
- 2025-08-28 AU AU2025223814A patent/AU2025223814A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6618854B2 (ja) | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド | |
| CN107074928B (zh) | 新型猫促红细胞生成素受体激动剂 | |
| HRP20250309T1 (hr) | Proteini s dvostrukom funkcijom i farmaceutski pripravak koji ih sadrži | |
| JP2008500373A5 (cg-RX-API-DMAC7.html) | ||
| JPH07508025A (ja) | インスリン様増殖因子(igf−1)類似体 | |
| US20180028676A1 (en) | Methods and compositions for treatment of forbes-cori disease | |
| JP2014524908A5 (cg-RX-API-DMAC7.html) | ||
| JP2015522576A (ja) | 血小板由来成長因子に結合する設計アンキリンリピートタンパク質 | |
| JP2024532503A5 (cg-RX-API-DMAC7.html) | ||
| US20070244041A1 (en) | Peptide Yy Analogues | |
| JP2021512159A5 (cg-RX-API-DMAC7.html) | ||
| TW201536814A (zh) | 用於治療心臟衰竭之合成環狀多肽 | |
| JP2023040169A5 (cg-RX-API-DMAC7.html) | ||
| CN102482324A (zh) | 能够抑制自身免疫、炎症和癌症进程的新型趋化因子结合多肽 | |
| AU2022413461A1 (en) | Designed repeat domains with dual binding specificity and their use | |
| CN116615251A (zh) | 包含glp1肽模拟物的抗体-药物缀合物及其用途 | |
| JP2026501203A (ja) | アクチビン受容体iib型バリアント及びその使用 | |
| EP1590458A2 (en) | Bradykinin b2 receptor antagonist peptide from amphibian skin | |
| MX2012005912A (es) | Conjugado de polipeptido. | |
| WO2025096921A1 (en) | Peptide acids as a glp1r agonist and antibody-drug conjugates thereof | |
| Mezo et al. | Structure–activity relationships of a peptide inhibitor of the human FcRn: human IgG interaction | |
| JP2022523047A5 (cg-RX-API-DMAC7.html) | ||
| JP2025516139A5 (cg-RX-API-DMAC7.html) | ||
| JP2024546916A5 (cg-RX-API-DMAC7.html) | ||
| JP2010535490A (ja) | インスリン様成長因子融合タンパク質 |